Phuong N. Huynh

Array ( [id] => 12523914 [patent_doc_number] => 10004802 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2018-06-26 [patent_title] => Tolerogenic synthetic nanocarriers for generating CD8+ regulatory T cells [patent_app_type] => utility [patent_app_number] => 13/457936 [patent_app_country] => US [patent_app_date] => 2012-04-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 1 [patent_figures_cnt] => 2 [patent_no_of_words] => 29618 [patent_no_of_claims] => 18 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 179 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13457936 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 8476752 [patent_doc_number] => 20120276159 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2012-11-01 [patent_title] => 'TOLEROGENIC SYNTHETIC NANOCARRIERS' [patent_app_type] => utility [patent_app_number] => 13/458021 [patent_app_country] => US [patent_app_date] => 2012-04-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 5 [patent_figures_cnt] => 5 [patent_no_of_words] => 32206 [patent_no_of_claims] => 27 [patent_no_of_ind_claims] => 8 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13458021 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 8982276 [patent_doc_number] => 08513390 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2013-08-20 [patent_title] => 'Modified antibody compositions, methods of making and using thereof' [patent_app_type] => utility [patent_app_number] => 13/455924 [patent_app_country] => US [patent_app_date] => 2012-04-25 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 36 [patent_figures_cnt] => 36 [patent_no_of_words] => 50788 [patent_no_of_claims] => 137 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 93 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13455924 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10141087 [patent_doc_number] => 09173874 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2015-11-03 [patent_title] => 'Anti-drug vaccines' [patent_app_type] => utility [patent_app_number] => 13/452019 [patent_app_country] => US [patent_app_date] => 2012-04-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 21 [patent_figures_cnt] => 33 [patent_no_of_words] => 8997 [patent_no_of_claims] => 13 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 20 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13452019 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 9435463 [patent_doc_number] => 20140113370 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2014-04-24 [patent_title] => 'FC FUSION PROTEINS COMPRISING NOVEL LINKERS OR ARRANGEMENTS' [patent_app_type] => utility [patent_app_number] => 14/111327 [patent_app_country] => US [patent_app_date] => 2012-04-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 32 [patent_figures_cnt] => 32 [patent_no_of_words] => 29010 [patent_no_of_claims] => 23 [patent_no_of_ind_claims] => 5 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14111327 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 9421238 [patent_doc_number] => 20140105889 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2014-04-17 [patent_title] => 'METHOD FOR ALTERING PLASMA RETENTION AND IMMUNOGENICITY OF ANTIGEN-BINDING MOLECULE' [patent_app_type] => utility [patent_app_number] => 14/007947 [patent_app_country] => US [patent_app_date] => 2012-03-30 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 65 [patent_figures_cnt] => 65 [patent_no_of_words] => 130668 [patent_no_of_claims] => 45 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14007947 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 8429683 [patent_doc_number] => 20120251558 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2012-10-04 [patent_title] => 'ANTIBODY-DRUG CONJUGATES' [patent_app_type] => utility [patent_app_number] => 13/435731 [patent_app_country] => US [patent_app_date] => 2012-03-30 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 10578 [patent_no_of_claims] => 8 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13435731 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11343530 [patent_doc_number] => 09527925 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2016-12-27 [patent_title] => 'Bispecific binding molecules binding to VEGF and ANG2' [patent_app_type] => utility [patent_app_number] => 13/433359 [patent_app_country] => US [patent_app_date] => 2012-03-29 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 135 [patent_figures_cnt] => 138 [patent_no_of_words] => 33910 [patent_no_of_claims] => 24 [patent_no_of_ind_claims] => 7 [patent_words_short_claim] => 15 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13433359 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 9435015 [patent_doc_number] => 20140112922 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2014-04-24 [patent_title] => 'TARGETED PROTEIN SILENCING USING CHIMERAS BETWEEN ANTIBODIES AND UBIQUITINATION ENZYMES' [patent_app_type] => utility [patent_app_number] => 14/007784 [patent_app_country] => US [patent_app_date] => 2012-03-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 6 [patent_figures_cnt] => 6 [patent_no_of_words] => 16604 [patent_no_of_claims] => 35 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14007784 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 8858129 [patent_doc_number] => 08460662 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2013-06-11 [patent_title] => 'Compositions and methods relating to anti-IGF-1 receptor antibodies' [patent_app_type] => utility [patent_app_number] => 13/432472 [patent_app_country] => US [patent_app_date] => 2012-03-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 32 [patent_figures_cnt] => 43 [patent_no_of_words] => 46697 [patent_no_of_claims] => 21 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 189 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13432472 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12960304 [patent_doc_number] => 09872904 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2018-01-23 [patent_title] => Photoimmunoconjugates for use in photodynamic therapy [patent_app_type] => utility [patent_app_number] => 14/381386 [patent_app_country] => US [patent_app_date] => 2012-03-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 5 [patent_figures_cnt] => 5 [patent_no_of_words] => 5360 [patent_no_of_claims] => 22 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 50 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14381386 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 8698001 [patent_doc_number] => 20130060010 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2013-03-07 [patent_title] => 'DESIGN AND DEVELOPMENT OF MASKED THERAPEUTIC ANTIBODIES TO LIMIT OFF-TARGET EFFECTS' [patent_app_type] => utility [patent_app_number] => 13/424272 [patent_app_country] => US [patent_app_date] => 2012-03-19 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 42 [patent_figures_cnt] => 42 [patent_no_of_words] => 13463 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13424272 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 8523754 [patent_doc_number] => 20120323162 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2012-12-20 [patent_title] => 'Methods and Compositions for Treating Conditions of the Eye' [patent_app_type] => utility [patent_app_number] => 13/422462 [patent_app_country] => US [patent_app_date] => 2012-03-16 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 6 [patent_figures_cnt] => 6 [patent_no_of_words] => 13437 [patent_no_of_claims] => 14 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13422462 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 8523754 [patent_doc_number] => 20120323162 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2012-12-20 [patent_title] => 'Methods and Compositions for Treating Conditions of the Eye' [patent_app_type] => utility [patent_app_number] => 13/422462 [patent_app_country] => US [patent_app_date] => 2012-03-16 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 6 [patent_figures_cnt] => 6 [patent_no_of_words] => 13437 [patent_no_of_claims] => 14 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13422462 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11561719 [patent_doc_number] => 09624291 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2017-04-18 [patent_title] => 'Bi- and monospecific, asymmetric antibodies and methods of generating the same' [patent_app_type] => utility [patent_app_number] => 14/005580 [patent_app_country] => US [patent_app_date] => 2012-03-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 25 [patent_figures_cnt] => 46 [patent_no_of_words] => 22215 [patent_no_of_claims] => 8 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 194 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14005580 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 9204904 [patent_doc_number] => 20140004081 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2014-01-02 [patent_title] => 'Re-Directed Immunotherapy' [patent_app_type] => utility [patent_app_number] => 14/005452 [patent_app_country] => US [patent_app_date] => 2012-03-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 20 [patent_figures_cnt] => 20 [patent_no_of_words] => 35495 [patent_no_of_claims] => 38 [patent_no_of_ind_claims] => 23 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14005452 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 9823109 [patent_doc_number] => 08932593 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2015-01-13 [patent_title] => 'Methods for generating stably linked complexes composed of homodimers, homotetramers or dimers of dimers and uses' [patent_app_type] => utility [patent_app_number] => 13/419614 [patent_app_country] => US [patent_app_date] => 2012-03-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 27 [patent_figures_cnt] => 28 [patent_no_of_words] => 22449 [patent_no_of_claims] => 13 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 74 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13419614 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 9330115 [patent_doc_number] => 20140056897 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2014-02-27 [patent_title] => 'BISPECIFIC THREE-CHAIN ANTIBODY-LIKE MOLECULES' [patent_app_type] => utility [patent_app_number] => 14/001250 [patent_app_country] => US [patent_app_date] => 2012-03-09 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 1 [patent_figures_cnt] => 1 [patent_no_of_words] => 19172 [patent_no_of_claims] => 28 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14001250 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 9019915 [patent_doc_number] => 08529898 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2013-09-10 [patent_title] => 'Activatable binding polypeptides and methods of identification and use thereof' [patent_app_type] => utility [patent_app_number] => 13/413447 [patent_app_country] => US [patent_app_date] => 2012-03-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 41 [patent_figures_cnt] => 45 [patent_no_of_words] => 40841 [patent_no_of_claims] => 29 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 79 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13413447 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 8381406 [patent_doc_number] => 20120225032 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2012-09-06 [patent_title] => 'Dimeric Alpha Interferon PEGylated Site-Specifically Shows Enhanced and Prolonged Efficacy in Vivo' [patent_app_type] => utility [patent_app_number] => 13/412816 [patent_app_country] => US [patent_app_date] => 2012-03-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 17 [patent_figures_cnt] => 17 [patent_no_of_words] => 20980 [patent_no_of_claims] => 14 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13412816 [rel_patent_id] =>[rel_patent_doc_number] =>)